Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LFWD Stock Forecast 2026-2027
$8.44
Current Price
$22.86M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to LFWD Price Targets
+255.5%
To High Target of $30.00
+137.0%
To Median Target of $20.00
+18.5%
To Low Target of $10.00
LFWD Price Momentum
+5.2%
1 Week Change
+19.4%
1 Month Change
-6.3%
1 Year Change
+22.0%
Year-to-Date Change
-23.1%
From 52W High of $10.98
+103.9%
From 52W Low of $4.14
📊 TOP ANALYST CALLS
Did LFWD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ReWalk is one of their latest high-conviction picks.
Latest LFWD Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, LFWD has a bullish consensus with a median price target of $20.00 (ranging from $10.00 to $30.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $8.44, the median forecast implies a 137.0% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LFWD Analyst Ratings
2
Buy
0
Hold
0
Sell
LFWD Price Target Range
Low
$10.00
Average
$20.00
High
$30.00
Current: $8.44
Latest LFWD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LFWD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 19, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 18, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 11, 2025 | Lake Street | Buy | Maintains | $N/A | |
| Mar 11, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 20, 2025 | Lake Street | Buy | Maintains | $N/A | |
| Feb 20, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 10, 2025 | Laidlaw & Co. | Buy | Initiates | $N/A | |
| Nov 13, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 16, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 16, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 28, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 15, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 14, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 10, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 3, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 12, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 24, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 15, 2022 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 10, 2022 | HC Wainwright & Co. | Buy | Maintains | $N/A |
Lifeward Ltd. (LFWD) Competitors
The following stocks are similar to ReWalk based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
LFWD
ReWalk Robotics
mkt cap
22.57M
Lifeward Ltd. (LFWD) Financial Data
Lifeward Ltd. has a market capitalization of $22.86M with a P/E ratio of -0.5x. The company generates $20.92M in trailing twelve-month revenue with a -123.7% profit margin.
Revenue growth is -22.1% quarter-over-quarter, while maintaining an operating margin of -123.3% and return on equity of -209.1%.
Valuation Metrics
Market Cap
$22.86M
Enterprise Value
$21.17M
P/E Ratio
-0.5x
PEG Ratio
0.0x
Price/Sales
1.1x
Growth & Margins
Revenue Growth (YoY)
-22.1%
Gross Margin
+34.2%
Operating Margin
-123.3%
Net Margin
-123.7%
EPS Growth
-22.1%
Financial Health
Cash/Price Ratio
+48.1%
Current Ratio
2.4x
Debt/Equity
140.1x
ROE
-209.1%
ROA
-35.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lifeward Ltd. (LFWD) Business Model
About Lifeward Ltd.
What They Do
Develops wearable robotic exoskeletons for rehabilitation.
Business Model
Lifeward Ltd. generates revenue by designing, developing, and marketing advanced wearable robotic exoskeletons and other rehabilitation technologies. Their products are sold to rehabilitation hospitals, outpatient clinics, and directly to patients, facilitating therapy programs aimed at improving mobility and functional independence.
Additional Information
The company is headquartered in Hudson, Massachusetts, and operates in the medical device sector, focusing on neurologic, orthopedic, and general rehabilitation markets. Lifeward’s innovative solutions cater to individuals with spinal cord injuries and other significant walking impairments, positioning the company as a leader in technology-assisted rehabilitation.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
81
CEO
Mr. William Mark Grant
Country
Israel
IPO Year
2014
Website
golifeward.comLifeward Ltd. (LFWD) Latest News & Analysis
Latest News
Quick Summary
A veteran physician with 30 years of experience in rehabilitation medicine and expertise in neuroscience, mobility technologies, and metabolic disease has joined the team.
Why It Matters
The appointment of a seasoned expert in rehabilitation medicine and neuroscience could signal advancements in innovative health technologies, potentially enhancing company value and market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lifeward Ltd. (LFWD) held its Q1 2026 earnings call, providing financial results and insights into company performance. Further details can help assess investment potential.
Why It Matters
Lifeward Ltd.'s Q1 2026 earnings reveal financial performance and growth potential, impacting stock valuation, investor sentiment, and future investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Oramed closed a strategic transaction, securing $10M financing and acquiring Oratech, which includes $6.5M cash and oral insulin technology. Operating cash burn reduced by 33% year-over-year. Conference call at 8:30 AM ET.
Why It Matters
Oramed's strategic acquisition enhances its product pipeline and cash position, reduces burn rate, and improves operational efficiency, signaling potential growth in biomed and neurorehabilitation markets.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lifeward (LFWD) reported a quarterly loss of $6.7 per share, significantly higher than the expected loss of $0.34, and up from a loss of $5.52 per share a year earlier.
Why It Matters
Lifeward's significant quarterly loss far exceeds expectations, indicating worsening financial health and potential challenges ahead, which can negatively impact investor confidence and stock price.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Lifeward Ltd. (Nasdaq: LFWD) will release its Q1 2026 financial results on May 15, 2026, before U.S. market opening. The company focuses on neurorehabilitation products and biomedical innovations.
Why It Matters
Lifeward's upcoming financial results could impact stock performance, offering insights into growth, profitability, and market position in the biomedical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lifeward reports a 3% lifetime fracture prevalence and zero fractures in 97 German users since 2018, supporting the safety of ReWalk for spinal cord injury mobility.
Why It Matters
The low fracture rates and safety profile of ReWalk enhance its market potential, signaling growth opportunities in spinal cord injury treatments, which can attract investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About LFWD Stock
What is Lifeward Ltd.'s (LFWD) stock forecast for 2027?
Based on our analysis of 1 Wall Street analysts, Lifeward Ltd. (LFWD) has a median price target of $20.00. The highest price target is $30.00 and the lowest is $10.00.
Is LFWD stock a good investment in 2027?
According to current analyst ratings, LFWD has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.44. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LFWD stock?
Wall Street analysts predict LFWD stock could reach $20.00 in the next 12 months. This represents a 137.0% increase from the current price of $8.44. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lifeward Ltd.'s business model?
Lifeward Ltd. generates revenue by designing, developing, and marketing advanced wearable robotic exoskeletons and other rehabilitation technologies. Their products are sold to rehabilitation hospitals, outpatient clinics, and directly to patients, facilitating therapy programs aimed at improving mobility and functional independence.
What is the highest forecasted price for LFWD Lifeward Ltd.?
The highest price target for LFWD is $30.00 from at , which represents a 255.5% increase from the current price of $8.44.
What is the lowest forecasted price for LFWD Lifeward Ltd.?
The lowest price target for LFWD is $10.00 from at , which represents a 18.5% increase from the current price of $8.44.
What is the overall LFWD consensus from analysts for Lifeward Ltd.?
The overall analyst consensus for LFWD is bullish. Out of 1 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $20.00.
How accurate are LFWD stock price projections?
Stock price projections, including those for Lifeward Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 10, 2026 3:10 AM UTC